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We analysed the 5-year relative survival among 4473 breast cancer cases diagnosed in 1990–1992 from cancer registries in Estonia,
France, Italy, Spain, the Netherlands and the UK. Among eight categories based on ICD-O codes (infiltrating ductal carcinoma, lobular
plus mixed carcinoma, comedocarcinoma, ‘special types’, medullary carcinoma, not otherwise specified (NOS) carcinoma, other
carcinoma and cancer without microscopic confirmation), the 5-year relative survival ranged from 66% (95% CI 61–71) for NOS
carcinoma to 95% (95% CI 90–100) for special types (tubular, apocrine, cribriform, papillary, mucinous and signet ring cell); 27%
(95% CI 18–36) for cases without microscopic confirmation. Differences in 5-year relative survival by tumor morphology and
hormone receptor status were modelled using a multiple regression approach based on generalised linear models. Morphology and
hormone receptor status were confirmed as significant survival predictors in this population-based study, even after adjusting for age
and stage at diagnosis.
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Tumour morphology and hormone receptor status are established
predictors of breast cancer survival (Ruder et al, 1989; Northridge
et al, 1997; Early Breast Cancer Trialists’ Collaborative Group,
1998; Li et al, 2003). Detailed stage information is seldom available
in population-based studies and few have assessed the influence of
both these groups of predictors on prognosis using appropriate
statistical methods (Northridge et al, 1997; Li et al, 2003).
The EUROCARE high-resolution studies, which are principally
concerned with interpreting regional differences in survival, also
provide population-based information on biological prognostic
factors, such as tumour morphology and hormone receptor status,
as well as information on stage, diagnostic investigations and
therapy. Using such data, the present study aimed to examine, at
the population level, the influence of morphology and hormone
receptor status on breast cancer survival, adjusting by disease
stage and age at diagnosis.
MATERIAL AND METHODS
We analysed data on a representative sample of 4478 breast cancer
patients investigated in previous EUROCARE high-resolution
studies on breast cancer (Sant, 2001; Sant et al, 2003). All had
primary invasive breast cancer diagnosed in 1990–1992 in the
territories of 17 population-based cancer registries in six countries:
Estonia (national registry); France (Bas-Rhin, Calvados, Co ˆte d’Or,
Doubs, He ´rault, Ise `re, Somme, and Tarn); Italy (Firenze, Modena,
Ragusa and Varese); Spain (Granada); the Netherlands (Eindho-
ven) and the UK (Mersey and Thames). Details of the study design
and sampling have been published (Sant, 2001). At least 5 years of
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yfollow-up was available for all women. Each registry used its own
follow-up procedures. The UK registries updated the life status of
patients included in this study by linking death certificates to the
registry records; all other registries actively ascertained the life
status of cases from various sources of information (e.g. registry of
general practitioners, municipality files).
Detailed information on stage, diagnostic examinations and
treatment was collected according to a standardised protocol
(Sant, 2001). Most of the information required was obtained from
patients’ clinical records. However, in some cases these were
incomplete, and other records had to be examined (e.g. pathology
reports and discharge records).
ICD-O classification (Percy et al, 1990) was available for
all cases. A total of 4473 cases were included in the morpho-
logy analysis after excluding five erroneously classified cases
(Table 1). Based on the ICD-O code, we grouped the cases into
the following eight categories: infiltrating ductal carcinoma,
lobular plus mixed carcinoma, comedocarcinoma, the so-
called special types (77 tubular, five apocrine, 20 cribriform, 27
papillary, 77 mucinous and five signet ring cell carcinoma)
(Tavassoli and Devilee, 2003), medullary carcinoma, not otherwise
specified (NOS) carcinoma, other carcinoma (trabecular, acinar,
squamous, small cell, pilomatrix, transitional carcinoma, lympho-
epithelioma and carcinoid) and cancer without microscopic
confirmation.
Oestrogen and progesterone receptor status was classified into
five categories: negative, positive, test performed with unknown
result, test not performed and unknown whether performed or not.
Receptor status, in particular whether positive or negative, was
determined directly from the clinical record: absolute values were
not required by the study protocol.
Tumours were staged according to TNM rules (3rd edition)
(Spiessel et al, 1992). Pathological T and N categories were used for
women who underwent surgery; clinical T, N and M categories
used for women not treated surgically (approximately 10%).
We categorised tumour stage as follows: T1N0M0, T2-3N0M0,
T1-3NþM0, T4 M0, M1 and stage not specified.
Relative survival (5-year) was calculated by the Hakulinen
method (Hakulinen, 1982; Hakulinen and Abeywickrama, 1985)
with 95% confidence intervals (CI) calculated from the standard
error according to Greenwood’s (1926) method. Relative survival is
an estimate of the probability of cancer survival after adjusting for
competing causes of death determined from general population life
tables for women, specific for each country or registry.
Differences in 5-year relative survival by tumour morphology
and hormone receptor status were modelled with a recently
developed multiple regression approach based on generalised
linear models and adopting the Poisson assumption for the
observed number of deaths (Dickman et al, 2004). The relative
excess risks (RERs) derived from these models quantify the extent
to which the hazard of death in a given group differs from that in
the reference category, after taking into account the background
risk of death in the general population of each country or region.
The multivariable analyses only included cases from registries with
hormone receptor status available for X60% of operated cases
(2346 women; 52% of total). Cases from the registries of Firenze
(Florence), Somme, Granada, Mersey, Thames, Eindhoven and
Estonia were excluded (Table 1).
Age at diagnosis was categorised into o40 years, 40–49, 50–59
(reference category) and 60 years or over. Hormone receptor status
was grouped into four categories: both positive (ERþ PGRþ),
both negative (ER  PGR ), tests performed with one positive
result (ERþ or PGRþ) and cases with test not performed or
result unknown. All calculations were carried out using the Stata
statistical package (Stata Corporation, 2001).
RESULTS
Table 1 shows the total number of cases by registry together with
morphology and hormone receptor status and other indicators of
data completeness and quality. Overall 97% of cases were
microscopically confirmed (range 89–99%) and 90% were treated
surgically (range 74–95%). Infiltrating ductal carcinoma and NOS
Table 1 Total number of breast cancer cases by registry, with data quality indicators
Morphology
a Hormone receptor status
a
Country Registry No.
%
Microscopically
confirmed % Operated
% Infiltrating
ductal
carcinoma
% Carcinoma
NOS
% Oestrogen
available
% Progesterone
available
Italy: Firenze 207 93.7 95.2 49.7 0.5 40.6 34.5
Modena 302 97.4 95.4 80.2 1.4 70.8 69.1
Ragusa 217 88.8 87.6 60.0 3.7 65.3 62.1
Varese 467 96.2 90.8 70.7 1.4 70.5 68.4
France: Bas-Rhin 208 99.5 93.7 82.0 0.0 84.6 84.6
Calvados 305 98.7 90.5 69.2 6.9 67.7 68.1
Cote d’Or 251 99.2 93.2 74.4 0.0 89.3 89.3
Doubs 224 96.4 92.4 73.4 1.9 68.1 67.6
Herault 202 97.5 89.1 40.6 38.9 68.9 67.2
Ise `re 202 98.5 95.5 74.6 4.1 84.5 82.9
Somme 244 99.2 90.2 36.4 54.5 47.3 46.8
Tarn 173 97.1 91.9 75.5 3.1 72.3 71.7
Spain: Granada 179 97.2 88.3 77.8 3.2 33.5 33.5
UK: Mersey 219 96.4 87.7 78.1 3.1 0.0 0.0
Thames 340 94.7 83.2 70.0 10.9 2.1 0.0
NL: Eindhoven 509 98.6 92.7 71.2 1.7 81.4 52.7
Estonia 224 96.4 74.5 78.4 1.8 28.1 0.0
Total 4473 96.9 90.2 68.8 7.4 59.6 53.9
aPercentages calculated on operated patients.
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ycarcinoma accounted for 69 and 7% of the surgically treated cases,
respectively, with conspicuous variation across registries (36–82%
and 0–54%, respectively). Oestrogen receptor status was available
in 60% of operated cases (range 0–89%) and progesterone receptor
status was available in 54% of operated cases (range 0–85%).
Table 2 shows the 5-year relative survival by morphology group,
for all cases. The largest morphological categories were infiltrating
ductal carcinoma (65%), lobular or mixed carcinoma (12%) and
NOS carcinoma (10%). The other categories contained many fewer
cases. Of all cases, 3% were not confirmed microscopically.
The 5-year relative survival was 81% (95% CI 80–82) for
infiltrating ductal carcinoma, 87% for comedocarcinoma (95% CI
80–94), 86% for lobular or mixed carcinoma (95% CI 82–90) and
86% for medullary carcinoma (95% CI 76–96). The special types
category had the greatest survival (95%; 95% CI 90–100), NOS
carcinoma had the second lowest survival (66%; 95% CI 61–71)
and cases without microscopic confirmation the lowest survival
(27%; 95% CI 18–36).
Table 3 shows hormone receptor status in 2346 cases from a
subset of 10 registries with this information available for X60% of
operated women, together with mean age at diagnosis and 5-year
relative survival. A total of 1222 (52%) of these women had
oestrogen-positive cancers, 1091 (47%) had progesterone-positive
cancers. More specifically, 980 (42%) had both oestrogen- and
progesterone-positive tumours, while 393 (17%) were negative
for both oestrogen and progesterone receptors (see Table 4). The
mean age of women with oestrogen-positive cancers was slightly
greater than for those with oestrogen-negative cancers, but did not
differ between those with progesterone-negative and progesterone-
positive tumours.
Women with oestrogen receptor-positive disease had better
survival (90%; 95% CI 88–92) than those with oestrogen receptor-
negative disease (77%; 95% CI 73–81). Similarly, women with
progesterone receptor-positive disease had better survival (90%;
95% CI 88–92) than those with progesterone receptor-negative
disease (79%; 95% CI 75–83). Women for whom information on
receptor status was not available had intermediate 5-year relative
survival (86%, 95% CI 82–90). The survival of patients with both
receptors positive was 90% (95% CI 87–93) compared to 73% (95%
CI 68–78) for those with both receptors negative (data not shown).
Table 4 shows tumour morphology in relation to positive
hormone receptor status for the cases with available information
on oestrogen (n¼1731) or progesterone status (n¼1704) from the
10 registries, with information available in 60% or more of
operated cases. The lobular plus mixed carcinoma category had the
highest proportions of cases with positive receptor status (82% for
oestrogen and 70% for progesterone), while the medullary
carcinoma category had the lowest proportions with positive
receptors (26% for oestrogen and 35% for progesterone). In the
other morphologic groups, the proportions ranged from 48 to 71%
for oestrogen and from 50 to 67% for progesterone.
For most morphologic categories, the proportion with positive
oestrogen receptors was higher than the proportion with positive
progesterone receptors, exceptions being comedocarcinoma and
medullary carcinoma.
Table 5 shows the results of the multivariable regression analysis
to determine the RERs of death for morphologic group, age, stage
at diagnosis and hormone receptor status, in each case taking into
account the influence of the other variables.
Comedocarcinoma, (0.34, 95% CI 0.12–0.98), special types
(0.35, 95% CI 0.12–0.99) and lobular and mixed carcinoma (0.58,
95% CI 0.37–0.91) had lower RERs of death than infiltrating ductal
carcinoma (reference category). For the other carcinomas cate-
gory, the RER (1.38, 95% CI 0.72–2.63) was about 40% higher and
for the medullary carcinoma category the RER (1.19, 95% CI 0.49–
2.85) was about 20% higher than reference; the RER for NOS
carcinoma was 1.08 (95% CI 0.68–1.71). With respect to age, the
40–49 year age group had the lowest RER of death (0.71, 95% CI
0.49–1.02) compared to the 50–59 year reference category. With
respect to tumour stage, RERs increased with advancing stage and
in all cases were significantly higher than reference (T1N0M0).
Unspecified stage cancers had an intermediate RER.
Women positive for both hormone receptors (ERþ PGRþ)
had a significantly lower RER of death (0.32, 95% CI 0.24–0.43)
than those negative for both receptors (ER  PGR , reference). A
positive result for one receptor (ERþ or PGRþ) was also
significantly protective compared to reference (0.41; 0.28–0.62).
Women with receptors not determined or with unknown result
had an intermediate RER (0.49, 95% CI 0.35–0.67). In a separate
analysis of the only ERþ and only PGRþ groups, RERs were 0.39
(95% CI 0.24–0.62) and 0.51 (95% CI 0.27–0.97), respectively,
compared to the ER- PGR- reference (data not shown).
We also tested the two-way interactions: morphology and stage,
morphology and age, morphology and registry, hormone receptor
status and registry. None of these interactions was statistically
significant.
Table 2 Number of cases by morphologic group, with 5-year relative
survival (all participating registries)
Morphology No. %
5-year relative
survival (%) 95% CI
Infiltrating ductal
carcinoma
2886 65 81 80–82
Lobular and mixed
carcinoma
523 12 86 82–90
Comedocarcinoma 104 2 87 80–94
Special types
a 211 5 95 90–100
Medullary 62 1 86 76–96
NOS carcinoma 464 10 66 61–71
Other carcinoma
b 82 2 77 65–89
No microscopic
confirmation
141 3 27 18–36
Total 4473 100 79 78–80
aSpecial types: tubular, apocrine, cribriform, papillary, mucinous, signet ring cell
carcinoma.
bOther carcinoma: trabecular, acinar, squamous, small cell, pilomatrix,
transitional carcinoma, lymphoepithelioma and carcinoid.
Table 3 Hormone receptor status, with mean age at diagnosis and 5-year relative survival (cases from a subset of 10 registries with information on
receptor status available in X60% of operated cases)
Oestrogen Progesterone
No. (%) Mean age 5-year relative survival (%) 95% CI No. (%) Mean age 5-year relative survival (%) 95% CI
Positive 1222 52 61 90 88–92 1091 47 60 90 88–92
Negative 509 22 56 77 73–81 613 26 60 79 75–83
Not available 615 26 62 86 82–90 642 27 62 86 82–90
Total 2346 100 60 86 84–88 2346 100 60 86 84–88
Not available¼test not performed or unknown result.
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As in previous population-based and clinical studies (Ruder et al,
1989; Northridge et al, 1997; Early Breast Cancer Trialists’
Collaborative Group, 1998; Li et al, 2003), tumour morphology
and hormone receptor status are important predictors of breast
cancer survival. The 5-year survival varied from 66% for NOS
carcinoma to 95% for special type tumours, while patients with
oestrogen- and progesterone-positive tumours had better survival
(90%) than those negative for both receptors (73%). Morphology
and receptor status remained significant survival predictors after
adjusting for age and stage at diagnosis.
A strength of our study is that it is population-based (covering
all the cases in registry populations) and is therefore not
susceptible to the selection bias of clinical series. Detailed stage
at diagnosis not usually available in population-based studies and
age were taken account of in analysing the prognostic effects of
morphology and receptor status.
Previous studies on the present data set analysed the effect of
tumour stage on survival (Sant et al, 2003, 2004). We used this
detailed stage information – available in 92% of cases – to adjust
for stage in the multivariable analysis of prognostic effects of
morphology and receptor status. Although stage depends on the
number of axillary nodes examined, this number was similar for
each morphological group; thus, inclusion of number of nodes
examined in the model had little effect on the results (data not
shown).
Another strength of the study is that the effects of competing
causes of death were controlled for by estimating the relative
survival. Population-based studies on the SEER database, which
analysed the relative risk of breast cancer death according to
tumour morphology, did not estimate survival in this way. One of
these (Li et al, 2003) did not control for competing causes of death;
the other (Northridge et al, 1997) used cause-specific survival to
control for competing causes of death. It is also important to note
that only summary information on stage was available in these
studies (categories: localised disease, regional metastasis, distant
metastasis and unstaged) and the models did not adjust for
hormone receptor status.
Information on tumour morphology was satisfactorily complete
in the present study (97% of diagnoses confirmed microscopi-
cally). The morphology categories special type and comedocarci-
noma were associated with lower RERs of death than infiltracting
ductal carcinoma (Table 5). The special type category includes,
tubular, mucinous and papillary histotypes, which were reported
to have good prognoses in a previous population-based study
(Li et al, 2003), and in other studies (Cooper et al, 1978; Fisher et al,
1980; Wargotz and Silverberg, 1988; Ellis et al, 1992; Silverstein
et al, 1994; Pedersen et al, 1995; Reinfuss et al, 1995; Toikkanen
et al, 1997; Diab et al, 1999). Comedocarcinoma also had a
relatively good prognosis in a previous study (Li et al, 2003). As
expected, the categories other and NOS carcinoma had the lowest
survival in our study.
Adjustment for age and stage had only limited effects on RERs
for each morphologic category; in particular, rank did not change.
However, comedocarcinoma, other and NOS carcinoma were
generally diagnosed at a more advanced stage than other
morphologic categories, and their RERs decreased from 0.55 to
Table 4 Tumour morphology in relation to hormone receptor status for
cases with information available on oestrogen (n¼1731) and progesterone
(n¼1704) from the 10 registries with hormone receptor information
available in X60% operated cases
Morphology
Oestrogen
positive (%)
Progesterone
positive (%)
Infiltrating ductal carcinoma 71 64
Comedocarcinoma 48 50
Lobular and mixed carcinoma 82 70
Special types 69 67
Medullary carcinoma 26 35
NOS carcinoma 64 60
Other carcinoma 66 53
Table 5 Relative excess risks (RERs) of death by morphology, age, disease stage and hormone receptor status (cases from the 10 registries with hormone
receptor information available in X60% operated cases)
No of cases RER 95% CI
Morphology Infiltrating ductal carcinoma 1659 1
Lobular and mixed carcinoma 297 0.58 0.37–0.91
Comedocarcinoma 66 0.34 0.12–0.98
Special types 111 0.35 0.12–0.99
Medullary carcinoma 34 1.19 0.49–2.85
NOS carcinoma 130 1.08 0.68–1.71
Other carcinoma 49 1.38 0.72–2.63
Age 23–39 144 0.96 0.60–1.53
40–49 426 0.71 0.49–1.02
50–59 486 1
60–99 1290 0.86 0.64–1.14
Stage T1N0M0 819 1
T2-3N0M0 443 3.82 1.94–7.51
T1-3N+M0 789 9.26 5.05–16.97
T4 M0 115 17.78 9.07–34.83
M1 72 56.39 29.42–108.09
Stage not specified 108 6.04 2.42–15.11
Hormone receptors ER  PGR 
a 393 1
ER+PGR+
b 980 0.32 0.24–0.43
Either ER+ or PGR+
c 353 0.41 0.28–0.62
Other
d 620 0.49 0.35–0.67
aER  PGR ¼both negative results.
bER+ PGR+¼both positive results.
cEither ER+ or PGR+¼tests performed with one positive result; in most cases, it is not known
whether the other test was performed.
dOther¼tests not performed or unknown result.
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these adjustments (data not shown). The overall proportion of
NOS carcinomas was 7%, compared to 5% in the US SEER
populations (Northridge et al, 1997).
A possible weakness of our study is that the morphologic
diagnoses may not be entirely comparable between registries, as is
suggested by the fact that, although all registries coded tumour
morphology using ICD-O, the proportion of NOS carcinomas
varied considerably between registries (Table 1), indicating that
the quality of morphology data also varied. Thus, in Firenze, the
proportions of NOS and infiltrating ductal carcinoma were
strikingly low because pathologists systematically search for
lobular or other components, so that a proportion of these cases
are classified as mixed (lobular plus ductal) or special type
carcinoma. Only one registry with a high proportion of NOS
carcinomas (Herault, 39%) was included in the multivariable
analysis, while the average proportion of NOS carcinomas in the
other nine registries was around 2%. To identify misclassification
in morphology coding, we looked for an interaction between
morphology and registry, but found none. In addition, sensitivity
analyses excluding Herault and Somme did not produce sub-
stantial changes in morphology RERs. We grouped tubular,
apocrine, cribriform, papillary and mucinous carcinomas into
the special type category because of their small numbers and
because all had similarly favourable survival. Larger studies may
be able to assign meaningful individual RERs to these rarer
histotypes.
We are aware of no other studies that considered the prognostic
influence of receptor status on the prognostic effect of morpho-
logy. Receptor status is not usually available to cancer registries,
and for various reasons registries may not be able to obtain this
information systematically. The percentage of our cases with
known receptor status was lower than reported elsewhere (Early
Breast Cancer Trialists’ Collaborative Group, 1998; Chu et al, 2001;
Chu and Anderson, 2002; Colditz et al, 2004). To enhance its
reliability, our analysis was confined to registries with receptor
status information available in at least 60% of cases. In these
registries, the proportions of cases positive for oestrogen and
progesterone receptors were similar to those of these other studies.
It is relevant that we do not know the criteria for deciding
whether a tumour was receptor positive or negative, or to what
extent these were uniform across our registry areas, a problem that
has been addressed elsewhere (Chapman et al, 1993, 1996). We
decided to collect the results as positive or negative. However, this
may have reduced accuracy, as we did not have the absolute values
against which to check the positive/negative result. To mitigate this
problem, we erected four particular categories: ERþ plus PGRþ;
ER  plus PGR ; either ERþ or PGRþ (with the other result very
often not known); and ‘other’ (cases with status unavailable or
unreliable). The first two categories are likely to contain the least
errors. As expected, ERþ plus PGRþ cases had better prognoses
than ER  plus PGR  cases; either ERþ or PGRþ cases also had
good prognoses, but less so than cases with both receptors present.
The RER of death for the ‘other’ category was intermediate,
suggesting that it contained considerable numbers of women
whose tumours were receptor positive. Like those for morphology,
RERs for receptor status did not change substantially when
adjusted by stage and morphology (not shown).
We did not include tamoxifen treatment in the multivariable
analysis, as information was incomplete, being often prescribed
during follow-up, and not entered on the primary treatment
record. However, we did analyse tamoxifen in all ERþ women,
since for most of these hormone treatment information was
available. Tamoxifen was found to be associated with a 10%
reduction in the RER of death compared with ERþ women not
prescribed the drug (results not presented) – a figure consistent
with reductions reported elsewhere (Early Breast Cancer Trialists’
Collaborative Group, 1998). We note that women in the 40–49 age
class (predominantly premenopausal) had the lowest RER of death,
consistent with previous findings (Langlands and Kerr, 1979;
Adami et al, 1986; Sant et al, 2003).
Our analysis has shown that EUROCARE high-resolution studies
are able to provide information on biological tumour charac-
teristics at the level of the population, in addition to their prin-
cipal aim of explaining regional and temporal survival differences.
It is important to continue efforts to improve the completeness
and quality of the data collected by population-based cancer
registries.
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